Translational Continuity

Drug development is a high-risk endeavor, with over 90 percent of drug candidates that enter clinical trials falling short of obtaining final approval.¹ Many of these failures arise from unexpected toxicity or limited efficacy in humans, which researchers cannot anticipate because their early-stage models do not fully recapitulate human biology. In particular, animal models frequently fail to predict human outcomes because species-specific differences in organ systems, drug metabolism, and cellular responses can lead to misleading results. Consequently, scientists need more human-relevant preclinical models.

Why human-relevant models are needed

Species-specific differences can affect several aspects of drug response, including:

Drug metabolism and pharmacokinetics
Immune system function
Cellular signalling pathways
Tissue structure and organ physiology

These differences contribute to a translational gap between preclinical findings and clinical outcomes, helping explain why so many drug candidates fail during development..¹

Closing the translational continuity gap with new approach methodologies

In response to these translational challenges, the United States Congress passed the US Food and Drug Administration (FDA) Modernization Act 2.0 in 2022, which removed the requirement for animal studies to assess a new drug’s safety and efficacy.² Instead, the agency now accepts data from validated alternative approaches, such as organoids, advanced cell-based assays, organ-on-chip systems, or computational models. Known collectively as new approach methodologies (NAMs), these systems better model features of healthy and diseased human tissues, including cellular diversity, tissue architecture, and molecular signaling.

Among these approaches, organoids have gained particular attention. Derived from human pluripotent stem cells, organoids are three-dimensional (3D), multicellular in vitro models that capture key structural and functional features of native tissues.³ Their ability to model human-specific biology makes them valuable tools for translational research and drug development. As researchers incorporate organoids and other NAMs into workflows to complement or replace animal studies, they must ensure that the models deliver reliable results. Achieving this depends not only on biological fidelity but also on the quality and consistency of the reagents used alongside them.

The risks associated with impure functional antibodies

Functional antibodies are key reagents used for various applications, including altering signaling pathways, activating immune cells, neutralizing cytokines, and eliminating specific cell types.⁴ Scientists leverage these proteins to study physiological processes and disease mechanisms in preclinical models, such as organoids and mice, across cancer, neuroscience, immunology, and infectious disease research.

However, antibodies must be high-quality, high-performance, and target-specific to ensure accurate and reproducible results.This requirement is especially important in organoid studies, where sensitive cellular systems can respond to even trace levels of contaminants.

Common impurities affecting organoid studies include:

Endotoxins
Carrier proteins
Preservatives
Stabilisers

Even low levels of these contaminants may trigger cytokine release, inflammatory responses, or cellular stress, potentially altering organoid morphology, viability, and function. Off-target activity and cytotoxic artifacts can further compromise data quality, leading to inaccurate conclusions about a therapeutic candidate's safety or efficacy during screening studies in organoid and 3D bioprinted models.⁵

These concerns are amplified when working with patient-derived organoids, where limited sample availability makes experimental consistency particularly important.

High-purity functional antibodies safeguard reliable organoid research

With sensitive organoid models, selecting rigorously purified antibodies is essential to ensure dependable and predictive research outcomes. Bio X Cell offers ultrapure functional antibodies against human and murine targets that are ready for use in organoids and organ-on-chip systems. Their formulations contain low levels of contaminants, including endotoxins, preservatives, carrier proteins, and stabilizers, making them well-suited for use with valuable patient-derived organoids. The company’s organoid portfolio includes antibodies that block or activate key signaling pathways in immuno-oncology and autoimmune disease research, such as anti-mouse or anti-human PD-1, anti-mouse or anti-human IFNγ, and anti-mouse 4-1BB.

Using a single, consistent formulation across models, such as human xenograft mouse models and human organoids, also reduces variability introduced by switching reagents between in vitro and in vivo experiments. Bio X Cell’s portfolio of in vivo-ready antibodies supports seamless transitions between model systems, allowing researchers to use the same antibody across organoid and animal studies while maintaining experimental continuity.

Overall, Bio X Cell’s functional antibodies for organoids deliver consistent performance while minimizing contaminant-associated artifacts, helping preserve translational relevance.